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ABSTRACT 
Since it was pioneered successfully, renal transplantation remains the only option for patients 
with stage-5 chronic, severe, and end-stage renal disease for whom dialysis treatment 
complications preclude its continued use.  Currently, and historically, the supply of suitable 
living-donor allografts is far less than their clinical need, and this gap cannot be offset by 
transplanting available cadaveric kidneys.  Immuno-suppressive and -induction therapies have 
been used to impair the recipients’ immune response against the allograft. Without such 
therapies many recipients’ immune systems would reject the organ, causing the patient to 
again experience renal failure.  It is therefore incumbent upon the public health community to 
ascertain the most effective treatment modality for transplanted organs to ensure that these 
limited resources are utilized in the most efficient manner possible. 
Thymoglobulin and Basiliximab induction therapies are two induction treatments available 
clinically for kidney transplantation.  Within this study, patients undergoing treatment using either 
of these induction-agents had their circulating T cell phenotypes analyzed and compared.  The 
goal of this study was to produce a statistical model, based on Generalized Estimating Equation 
methodology, that would predict episodes of acute cellular rejection (ACR) between the day of the  
transplant and up to one year after transplantation.  The selection of potential covariates was based 
upon previously identified T cell markers. 
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Due to small sample size, missing data, and both left- and right-truncation of the data, 
the model was not able discriminate between patients that underwent ACR from those that did 
not based upon the a priori markers of interest. However, the analysis did identify different 
memory T cell proportions that may be predictive of ACR in patients treated with 
Thymoglobulin or Basiliximab and warrants further study.  The public health impact of a 
predictive model would be to increase the quality and duration of life in individual patients and 
reduce the burden of End Stage Renal Disease (ESRD) within the US population as a whole. 
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1.0  INTRODUCTION 
Chronic stage-5 kidney disease, also called end-stage renal disease (ESRD), is a persistent disease 
endemic within the United States.  From 1996 to 2006 the incidence rate (per million per year) of 
ESRD increased from 328.1 to 386.4.  Since its peak in 2006, the incidence rate fell to 352.2 in 
2013; however, the incident cases of ESRD have remained steady over the same time period at 
roughly 101,000 cases per year.  As of 2013, ESRD’s four main causes were diabetes, 
hypertension, glomerulonephritis, and cystic kidney disease comprising 53.4%, 34.9%, 9.2%, and 
2.6% of new cases, respectively.  As a result of the steady incidence and persistent nature of ESRD, 
as well as an etiology which includes a factor comorbid with another increasing public health 
concern, obesity, the prevalence of ESRD has increased steadily each year from 1996 to 2013.  
The primary means of treating ESRD is via hemodialysis or, more infrequently, peritoneal dialysis.  
Because dialysis treatments only address the symptoms of ESRD, these modalities do not reduce 
the prevalence of the disease.  Renal transplantation, however, addresses the cause of ESRD by 
providing the patient with a functional kidney, and eliminates the need for regular dialysis 
treatments.[1], [2] 
The first successful human kidney transplant was performed in 1954 by Dr. Joseph E. 
Murray in Boston’s Peter Bent Brigham Hospital (now Brigham and Women’s Hospital).[3]  While 
it was a remarkable feat of surgical technique, it was only a long-term successful transplant because 
the patient was given a kidney from his identical twin brother, meaning that the transplanted organ 
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was genetically identical (syngeneic) to the host.[4]  As a result, the new kidney did not face the 
typical host vs. allogenic (of different genetic composition) transplanted organ (allograft) 
immunological response seen in the transplantation of kidneys from one individual to another with 
non-identical DNA.  A common type of such an immunological response towards a solid organ 
transplant is acute cellular rejection.[5], [6] 
Acute cellular rejection (ACR) episodes are characterized by large numbers of infiltrating 
host immune cells.  Those cells can form dense clusters within the allograft tissue at particular 
locations, and they may also be profuse throughout the allograft.  The presence of such 
immunocellular infiltrate creates two functional threats to the longevity of the allograft: first, high 
numbers of activated, allograft-specific adaptive immune cells (such as T cells) directly damage 
the allograft; second, clusters of these cells can serve to facilitate proliferation of allograft-specific 
T cells that will further damage the allograft.[7]  Of particular interest are CD4 and CD8 memory 
cells, which are recognized as critical mediators of ACR, and T regulatory cells, which serve to 
blunt the activity of T cells that might cause ACR.[6]  For the duration of an ACR episode, the 
allograft’s ability to function is reduced, and even after the episode is resolved clinically, damage 
to the tissue persists.  As such, ACR episodes in kidney transplant recipients present a significant 
threat to the continued function of the kidney allograft, and may ultimately lead to the complete 
loss of the transplanted organ.[5] 
Due to the functional impact of episodes of ACR, their discovery after a patient becomes 
symptomatic is not ideal.  Currently they can only be defined pathologically via needle biopsy, a 
procedure which removes a small cylindrical tissue sample from the kidney allograft for 
histological analysis.  By the time they have been discovered, host immune cells have most likely 
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done permanent damage to the allograft, limiting its ability to function within its recipient and 
increasing the risk for additional ACR episodes.[6] 
While the benefits of preventing the loss of a kidney are dramatic for any particular 
recipient, from an epidemiological perspective, diminishing the rate of renal allograft loss from 
ACR is imperative.  The pool of potential transplant recipients continues to grow at a faster rate 
than the availability of donor allografts, and this has caused more patients to wait longer for 
transplants.  In 2002, 2012, and 2016, the number of patients awaiting kidney transplant (and the 
percentage waiting longer than 5 years for a transplants) was 51,004 (9.7%), 92,885 (13.9%), and 
99,333 (15.8%), respectively.[2], [8]  The loss of function of an allograft exacerbates the increasing 
disparity between donor organ availability and need.  In 2014 and 2015, the number of allografts 
transplanted into patients receiving their second transplant was 2,003 and 2,319, respectively, 
which accounted for 11.7% and 13.0% of all kidney transplants performed in those years.[2]  Once 
the primary allograft is lost, patients awaiting subsequent transplants experience longer wait-times, 
with 23.8% waiting longer than 5 years for another allograft compared with 14.6% waiting as long 
for their first allograft.[1]  Therefore, in order to reduce the burden of medical care required for 
patients after the failure of their primary kidney allograft, and reduce the waiting period for all 
patients receiving kidney transplants, a means of predicting ACR events before irreparable 
damage, or loss, of a kidney allograft occurs is needed. 
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2.0  CLINICAL BACKGROUND FOR RENAL TRANSPLANTATION 
The immune response to an allogenic transplant is for host’s immune cells to attack allogeneic 
cells and tissues that express foreign MHC molecules. Acute and chronic T cell mediated rejection 
(TCMR) are two means by which a functioning allograft can be harmed so severely that it will no 
longer function.[6], [9]  Great strides have been made in reducing the host response against 
allografts, and as a result, kidney transplantation is the best available treatment for patients 
experiencing end-stage renal failure.[10]  In addition to the application of corticosteroids[11] and 
calcineurin inhibitors[12] used to suppress the recipient’s immune system, a method for reducing 
the risk of TCMR is the use of induction therapy at the time of the organ implantation.[13], [14], [15], 
[16] 
Induction therapy artificially induces immunological non-response to the allograft by 
means of manipulation of the hosts’ adaptive and/or innate immune systems.  Depleting 
(Thymoglobulin) and non-depleting (Basiliximab) therapies are currently FDA approved and 
available in the clinic.  While tolerance has been achieved in animal models with different 
induction therapy regimens, complete and lasting tolerance induction remains elusive in the 
field of human solid organ transplant.[13], [17], [18]  Allograft tolerance is the ultimate goal of 
transplantation research, and for the purposes here, it will be defined as the absence of host 
immunological attack of, or damage to, the allograft.  This definition includes insults to the 
allograft caused by both the innate and adaptive immune systems and all sub-categories 
thereof, i.e., TCMR, ACR, chronic humoral rejection, dendritic cell mediated rejection, etc.[7], 
[9] 
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2.1 RENAL ALLOGRAFT OUTCOMES 
The rates for long-term renal allograft survival have improved markedly since the advent of new 
pharmacological modalities.  The half-life of deceased donor renal allografts increased from 6.6 
years in 1989 to 8.0 years in 1995 then 8.8 years in 2005.[19]  Additionally, survival rates of 
transplanted kidneys have reached 92.0% and 96.5% for patients receiving deceased- and living-
donor allografts, respectively, one year after transplantation.[19]  While strides have been made in 
prolonging long-term graft survival in kidney transplant patients, there is still a significant, and 
persistent, proportion of recipients who experience ACR fewer than 90 days after transplantation, 
despite increasingly potent inductive and immunosuppressive regimens.[5]  Thymoglobulin® and 
Basiliximab have been shown to lower the incidence of ACR episodes versus placebo and previous 
treatment modalities, and are considered to be part of standard-of-care drug protocols for patients 
receiving renal allografts.[20], [21] 
Despite the known benefits of using induction protocols, their use also has drawbacks.  
When T cell depleting agents, such as Thymoglobulin, are used, the patients’ immune cells 
gradually become reconstituted.  The new populations of T cells quickly fill the place of T cell 
populations which developed over the patients’ lifetimes.  Therefore, the reconstituted T cell 
memory subsets differ from those that were depleted, and the new subsets that proliferate in the 
patient are associated with increased instances of delayed ACR.[15], [19] 
In addition, the non-depleting agents, such as Basiliximab, lower regulatory T cells (TREG), 
which are associated with long-term graft survival and graft tolerance, by blocking the IL-2Rα 
ability to signal.[22], [23]  Thus, non-depleting induction agents also have the potential to interfere 
with natural regulatory mechanisms and potential to skew the T cell population to favor 
alloreactive T cells.[24]  This means that, while such therapies have been able to lengthen mean 
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graft survival of allografts, they have been shown to be imperfect treatments, as they defer attack 
on the allograft (albeit for years) rather than prevent the host’s rejection of the allograft.  Only 
through further exploration can it be known if the T cell memory profiles created by induction 
therapies can be further modulated to entirely avoid TCMR or ACR rather than simply postponing 
these allograft-damaging episodes. 
2.2 LYMPHOCYTE MARKERS 
Throughout this study phenotypic analysis and flow cytometry, are used to identify subsets of 
lymphocytes.  are used to identify subsets of lymphocytes. Receptors on the surface of the cells or 
transcription factors in the nucleus, were chosen to identify cells that play important roles during 
ACR or allograft acceptance. 
2.2.1 CD3, CD4, and CD8 
Clusters of differentiation (CD) -3, -4, and -8 are proteins expressed on the cellular surface of T 
cells and are markers of determining cellular type.  CD3 is the signaling component of the T cell 
receptor (TCR), and is used throughout this study to differentiate T cells from non-T cells.  CD4 
and CD8 are two different co-receptors for the TCR and are indicative of the particular 
functionality of T cells.  T cells have either CD4 or CD8 expression once they leave the thymus 
and circulate throughout the body, but not both.  CD4+ T cells are often called helper T cells as 
their release of cytokines upon antigen recognition influences the activation and proliferation of 
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cytotoxic T cells.  Cytotoxic T cells are CD8+, and they able to attack and kill cells with the use 
of perforin and granzymes proteins, which they produce upon activation.[25] 
2.2.2 CD45RO, CD45RA, and CD62L 
The transmembrane protein CD45 has multiple isoforms, but the two of interest here are CD45RO 
and CD45RA, of which only one is expressed on the surface of a T cell at a time.  CD62L, or L-
selectin, is a protein which drives cells into secondary lymphoid tissues such as lymph nodes, 
tonsils, and the spleen.  Using a matrix of CD45RO versus CD62L expression, T cells can be 
broken down into the four functional categories seen Table 2.1: [25] 
 
Table 2.1: T cell Memory Subsets Defined by CD45RO and CD62L 
 CD45RO- CD45RO+ 
CD62L+ Naïve (TN) Central Memory (TCM) 
CD62L- Effector Memory, RA+ (TEMRA) Effector memory (TEM) 
2.2.3 FoxP3 and CD25 
Forkhead box protein P3 (FoxP3) is located in the cellular nucleus.  This protein is an essential 
transcription regulator as it suppresses transcription of genes encoding for pro-inflammatory 
cytokines like interleukin-2 and interferon-gamma.  FoxP3 is used for the identification of TREG in 
CD4+ T cells along with a high (as opposed to low and medium) expression of CD25, a marker of 
activation of T cells, and a lack of CD127 (IL-7Rα) expression.[25] 
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2.2.4 T Cell Subsets of Interest 
The identification of subsets of immune cells depends upon the markers expressed by those cells.  
The subsets of interest identified from previous studies with similar cohorts, but a different 
induction agent, are TREG defined as being CD3+/CD4+/CD25hi/FoxP3+, CD4 TEM defined as 
being CD3+/CD4+/CD62L-/CD45RO+, and CD8 TEMRA defined as being CD3+/CD8+/ CD62L-
/CD45RO-.[17], [23], [26]  These cells types were examined in this study to determine if changes in 
their frequency could predict ACR episodes. 
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3.0  ANALYSIS METHODOLOGY 
General estimating equations (GEE), are a form of generalized linear models (GLM) that take into 
account correlation introduced from multiple measurements of an individual.[27] 
3.1 GENERALIZED LINEAR MODELS 
Generalized Linear Models (GLM) refers to a large class of statistical models employed to relate 
outcomes to linear combinations of predictor variables, which can be adapted for many different 
types of data.  These data types include, continuous, ordinal, count, rate, and binary. 
In its most basic form, the generalized linear model may be written as seen in Equation 3.1.[28] 
Equation 3.1    𝑦𝑦𝑖𝑖 =  𝛸𝛸𝑖𝑖𝛽𝛽 +  𝜀𝜀𝑖𝑖 ~ iid 𝑁𝑁(0,𝜎𝜎2) 
Equation 3.1 states that the expected value for the random variable, y, for a given case, i, 
may be predicted by the observed values of covariates for that case, Xi, multiplied by the 
coefficients for those covariates, β.  The error between the predicted value for a given case, yi, is 
accounted for by the error term, εi.  Sample error, ε, for this model is assumed to follow a normal 
distribution with a mean 0 and standard deviation, σ.  This assumption is a consequence of the 
foundational assumption that the sampled random variables in the model are independent and 
identically distributed (iid).[28] 
The distribution of expected values, μi, of Yi given observed values of Xi (shown in 
Equation 3.2) need not be normally distributed. 
Equation 3.2     𝜇𝜇𝑖𝑖 = 𝐸𝐸(𝑌𝑌𝑖𝑖|𝑋𝑋𝑖𝑖) 
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When fitting a GLM, the most appropriate distribution should be chosen in accordance 
with the observed data being fit to the model.  This is accomplished by utilizing a link function, 
defined in Equation 3.3.[28] 
Equation 3.3     𝑔𝑔(𝜇𝜇𝑖𝑖) = 𝜂𝜂𝑖𝑖 
In the special case of µ = η, the GLM would function the same as classical (Gaussian) 
linear models.  This is known as the identity link.  However, GLM can be easily fit for any type of 
statistical distribution from the exponential family (the pdf of whose “natural form” was described 
by McCullagh and Nelder (1989), shown in Equation 3.4) to allow proper specification of the 
outcome variable structure.  For a function that is a member of the exponential family, θ is the 
scalar parameter, φ is the dispersion parameter, and b(θ), a(φ), and c(y, φ) are known functions.[28] 
Equation 3.4   𝑓𝑓𝑌𝑌(𝑦𝑦|𝜃𝜃) = 𝑒𝑒𝑒𝑒𝑒𝑒 �𝑦𝑦𝑦𝑦−𝑏𝑏(𝑦𝑦)𝑎𝑎(𝜑𝜑) +  𝑐𝑐(𝑦𝑦,𝜑𝜑)� 
If the proper distribution of the data is identified, so too is the proper variance structure from 
which it comes, as the first derivative of b(θ) is the distribution’s mean, and its second derivative 
is the distribution’s variance.  It is important to note that θ in the equations above stand for any 
number of parameters, so GLM are able to account for an equally large number of variable 
coefficients, β.[28] 
3.1.1 GLM Assumptions 
Applying GLM requires that a set of assumptions be met in order for valid statistical inferences to 
be made.  The assumptions placed upon GLM are as follows: 
1) The data Y1, Y2,…, Yn are independently distributed, i.e., the cases are independent; 
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2) Yi, the dependent variable, need not be normally distributed, but it will typically take the 
distribution of one of the members of the exponential family; 
3) There is a linear relationship between the transformed dependent variable, via the link 
function, and the independent variables; 
4) Missing data are missing completely at random (MCAR); 
5) And, large sample approximations are valid for the data, as they are required for maximum 
likelihood estimation (MLE) used to estimate the parameter. 
Neither normal distribution of errors, nor homogeneity of variance need to be assumed in order to 
properly employ GLM.[28] 
3.1.2 GLM Limitations 
Generalized linear models have two main limitations.  First, only linear predictors may be used in 
the predictor components of the model.  Second, requiring independent responses explicitly 
precludes analysis of the type of individual clustering expected in longitudinal studies.[28] 
3.2 GENERALIZED ESTIMATING EQUATIONS 
The Generalized Estimating Equation (GEE) approach is a natural extension to GLM that relaxes 
the restriction of independent response.  This difference is key in using GEE for longitudinal data 
analysis.[27] 
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3.2.1 GLM and GEE Similarities 
The most important conceptual similarity between GLM and GEE is the types of models, and the 
types of hypotheses, they can address.  Both methods are designed to explore marginal models, 
i.e., show the risk of a population given a particular set of treatments or exposures, while only 
GLM can address conditional models, those designed to address the risk of an individual given 
certain parameter values.[27] 
3.2.2 Marginal GEE Models 
Marginal GEE models are designed and employed to explain population- or cohort-wide 
probability averages for an outcome based upon covariate values over time.  These probabilities 
average over the random-effects distribution of the population.  As such, the primary use of 
marginal models is to describe both the positive and negative effects of each covariate as it relates 
to an outcome of interest and also the magnitude of its influence over the outcome while accounting 
for within group correlation over time.[27] 
Marginal models can give probability for an outcome given treatment or exposures (in the 
binary case) or weighted risk against continuous variables that applies to the whole cohort.  The 
probability for a given case, pi, in a binary GLM model is shown in Equation 3.5 (given that Yi = 
1 indicates that the presence of a treatment or exposure), where Xi and β are the values for the 
case’s observed variables and model’s coefficients for the covariates, respectively.[27] 
Equation 3.5  𝑒𝑒𝑖𝑖 =  𝐸𝐸(𝑌𝑌𝑖𝑖|𝑋𝑋𝑖𝑖) =  𝑃𝑃(𝑌𝑌𝑖𝑖 = 1|𝑋𝑋𝑖𝑖) =  exp (𝑋𝑋𝑖𝑖𝛽𝛽)1+ exp (𝑋𝑋𝑖𝑖𝛽𝛽) 
The GLM equation above can be adapted to determine probabilities of outcomes in GEE 
(see Equation 3.6), and it can also be easily converted to determine odds ratios, OR, between 
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treatments or exposures (see Equation 3.8).  In Equation 3.6 the probability of an outcome at a 
given time-point, pij, is determined by the observed values of the covariates at all observed time-
points, Xij, and the values of the coefficients of the model, β, given that Yij equal to one indicates 
the outcome of interest.  In Equation 3.6, 3.7, and 3.8 the subscript i indicates a given subject and 
subscript j indicates a given time-point of observation.[27] 
Equation 3.6 𝑙𝑙𝑙𝑙𝑔𝑔𝑙𝑙𝑙𝑙(𝑒𝑒𝑖𝑖𝑖𝑖) =  𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖�𝑋𝑋𝑖𝑖𝑖𝑖� =  𝑃𝑃�𝑌𝑌𝑖𝑖𝑖𝑖 = 1�𝑋𝑋𝑖𝑖𝑖𝑖� =  𝛽𝛽𝑋𝑋𝑖𝑖𝑖𝑖 
Obtaining an OR from a GEE model for a given exposure or treatment can be done utilizing 
the coefficients of the model.  Equation 3.7 is a GEE model of the simplest case in which only a 
single, binary treatment or exposure variable, Xij, is observed.  The coefficients of the model shown 
in Equation 3.7 β0 and β1 are the baseline coefficient for all subjects observed and the coefficient 
associated with receiving treatment, respectively.[27] 
Equation 3.7 𝑙𝑙𝑙𝑙𝑔𝑔𝑙𝑙𝑙𝑙�𝑒𝑒𝑖𝑖𝑖𝑖� = 𝑃𝑃�𝑌𝑌𝑖𝑖𝑖𝑖 = 1�𝑋𝑋𝑖𝑖𝑖𝑖� =  𝛽𝛽0 + 𝛽𝛽1𝑋𝑋𝑖𝑖𝑖𝑖 
The OR of an outcome based on receiving a treatment or exposure given the model from 
Equation 3.7 can be found in Equation 3.8.  The OR is defined by ratios of probabilities of 
outcomes at observed time-points, Yij, conditioned on the treatment received at those times, Xij.[27] 
Equation 3.8 𝑂𝑂𝑂𝑂 = 𝑃𝑃�𝑌𝑌𝑖𝑖𝑖𝑖=1|𝑋𝑋𝑖𝑖𝑖𝑖=1� 𝑃𝑃�𝑌𝑌𝑖𝑖𝑖𝑖=0|𝑋𝑋𝑖𝑖𝑖𝑖=1��
𝑃𝑃�𝑌𝑌𝑖𝑖𝑖𝑖=1|𝑋𝑋𝑖𝑖𝑖𝑖=0� 𝑃𝑃�𝑌𝑌𝑖𝑖𝑖𝑖=0|𝑋𝑋𝑖𝑖𝑖𝑖=0��  = 𝑒𝑒𝑒𝑒𝑒𝑒(𝛽𝛽0+𝛽𝛽1)𝑒𝑒𝑒𝑒𝑒𝑒(𝛽𝛽0)  = 𝑒𝑒𝑒𝑒𝑒𝑒(𝛽𝛽1) 
3.2.3 GEE Assumptions 
As is the case with GLM, GEE analysis has a number of assumptions which must be met in order 
for the model to be employed correctly.  They are: [27] 
1) The data Y1, Y2,…, Yn are not independently distributed, i.e., the cases are correlated or 
clustered; 
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2) Covariates can have interaction terms and may be non-linear transforms of independent 
variables; 
3) Variance does not need to be homogenous between estimated parameters; 
4) Errors are correlated; and 
5) Missing data are MCAR. 
3.2.4 GEE Correlation Matrices 
In GEE, correlation matrices are used to account for the lack of independence in clustered 
observations.  Values for the matrix range from zero to one where zero indicates no correlation 
between observations in a cluster, and values approaching one indicate very high correlation 
between observations.  The matrix is arranged such that the first value in each column and row is 
for the first observation and each subsequent column and row is for each subsequent observation.  
Correlation matrices are always square with its main diagonal values equal to one.[27] 
GEE is robust relative to the incorrect specification of correlation structure, however, a model 
fit with the correct correlation structure will produce more accurate estimates of variable 
coefficients and standard errors for the coefficients.  For a GEE model fit to longitudinal data 
collected from patients it would be expected that the most appropriate correlation matrix would 
show that the closer observations are in time, the more highly they are correlated.  Stationary and 
Autoregressive correlation matrices are two examples with this type of time-dependence.  
Illustration of different correlation matrices is depicted in Table 3.1 where ρ is a given correlation 
value exclusively between zero and one.[27] 
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Table 3.1: Examples of GEE Correlation Matrices 
Independence Exchangeable Stationary (m=1) AR1 Unstructured 
�
1 0 00 1 00 0 1� �1 𝜌𝜌 𝜌𝜌𝜌𝜌 1 𝜌𝜌𝜌𝜌 𝜌𝜌 1� �1 𝜌𝜌 0𝜌𝜌 1 𝜌𝜌0 𝜌𝜌 1� � 1 𝜌𝜌 𝜌𝜌
2
𝜌𝜌 1 𝜌𝜌
𝜌𝜌2 𝜌𝜌 1 � � 1 𝜌𝜌12 𝜌𝜌13𝜌𝜌21 1 𝜌𝜌23𝜌𝜌31 𝜌𝜌32 1 � 
3.3 MODEL SELECTION CRITERIA 
As opposed to GLM, GEE relies on quasi-likelihood estimation rather than maximum likelihood 
estimation.  Thus, methods used for model selection in GLM, such as Akaike information criterion 
(AIC) and Bayesian information criterion (BIC) are inappropriate for GEE.  Quasi-likelihood 
under the independence model criterion (QIC) is an adaptation of AIC that can be used in its place 
when evaluating the value of one model over another within GEE.  The similarities between AIC 
and QIC can be seen in Equation 3.9 and 3.10, respectively.[29], [30] 
Equation 3.9    AIC =  −2𝐿𝐿𝐿𝐿 + 2𝑒𝑒 
Equation 3.10  QIC =  −2𝑄𝑄(?̂?𝜇; 𝐼𝐼) + 2𝑙𝑙𝑡𝑡𝑡𝑡𝑐𝑐𝑒𝑒(Ω�𝐼𝐼−1𝑉𝑉�𝑅𝑅) 
 In the Equations 3.9 and 3.10 above, LL stands for log likelihood, p indicates the number 
of parameters, 𝑄𝑄(?̂?𝜇; 𝐼𝐼) is the quasi-likelihood function with an estimated mean of ?̂?𝜇 given I, the 
independent covariance structure, 𝛺𝛺�𝐼𝐼 is the variance estimator under the independence correlation 
structure, and 𝑉𝑉�𝑅𝑅 is the robust variance estimator.  Both AIC and QIC, therefore, give lower values 
for models which have a higher (quasi-)likelihood and fewer parameters, all else being equal.  QIC 
can also be used to compare GEE models with different assigned covariance structures if they have 
the same parameters, as the values in the 𝑉𝑉�𝑅𝑅 matrix are dependent upon the chosen covariance 
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structure.  By selecting GEE models with the lowest QIC values, the most parsimonious model 
with the best parameters and goodness-of-fit may be chosen.[29], [30] 
 The last aspect of model selection resides in the inclusion, or not, of interaction terms.  If 
an interaction between covariates within a model is found to be significant, the parent model and 
the model constructed by adding the interaction term to it may be compared using a modification 
of QIC termed QICu.  QICu adds to the value of QIC in proportion to the number of parameters 
within the model.  As a result, when two models differ in only one parameter a QICu comparison 
will weigh the information added by the additional parameter against the preference for as 
parsimonious a model as possible.  Equation 3.11 retains the variable definitions from Equations 
3.9 and 3.10 and describes QICu.[30] 
Equation 3.11  𝑄𝑄𝐼𝐼𝑄𝑄𝑄𝑄 =  −2𝑄𝑄(?̂?𝜇; 𝐼𝐼) + 2𝑒𝑒 
3.4 GEE MODEL APPLICATION 
In order to test the hypotheses that TREG, CD4 TEM, and/or CD8 TEMRA distributions were important 
predictors of ACR events, GEE models were built.  The process of building these models began 
with description and cleaning the data, determining which parameters were statistically significant, 
construction and comparison of models containing statistically significant parameters, and 
ultimately testing the best model against the data to determine its utility in discerning between 
patients at higher risk of ACR episodes from those that were not. 
The strategy for parameter selection was to test parameters of interest individually against 
the binary outcome variable of a patient experiencing ACR on their subsequent or not, with the 
inclusion criterion being a p-value of 0.15 or less using the same GEE analysis intended for the 
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built model.  The a priori assumption of covariance was that the data would be auto-regressive 
due to intra-patient correlation. 
3.5 MISSING DATA AND GEE ANALYSIS 
Missing data are a problem for accurate analysis of data in most statistical setting.  When applying 
GEE to longitudinal data, thorough and accurate characterization of the type the missing data is 
paramount because incorrect specification of the type of missing data during analysis can lead to 
biased or inefficient estimators.[31]  Three types of missing data will be discussed: data missing 
completely at random (MCAR), data missing at random (MAR), and data missing not at random 
(MNAR).[32] 
3.5.1 MCAR 
Data are considered to be MCAR if failure to observe the data does not depend on the outcome of 
interest, observed covariate values, or unobserved data.  Simply put, if data are MCAR, the missing 
data constitutes a random sample of all data that could have been observed.  As a result, no bias is 
introduced into the inferences drawn from analyzing the data, and this type of missing data can be 
appropriately analyzed using GEE.[32] 
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3.5.2 MAR 
Data are MAR when the missingness of the observed data does not depend on the outcome of 
interest.  However, the MAR assumption is less restrictive than the MCAR assumption because it 
allows for the failure to observe data to depend upon unobserved data.  Because MCAR is a special 
case of MAR, all data that are MCAR are also MAR.[32]  Data that are MAR but not MCAR can 
introduce bias into GEE analysis.  Other methods that appropriately account for data being MAR, 
such as mixed models, need to be utilized for such data.[33] 
3.5.3 MNAR 
Data are MNAR when the failure to observe the data depends upon the data that could have been 
observed.  In this case, missing data mechanisms must often be explicitly modeled, and ultimately, 
statistical inferences found using this type of methodology will be sensitive to the accuracy with 
which the missing data are modeled.  Adding to the complexity MNAR data is that typically the 
assumptions made in developing these models may not be verifiable.[32] 
3.5.4 Study Data and the MCAR Assumption 
In order to analyze data using GEE the MCAR assumption must be met.  With data that are 
multivariate normal, Little’s MCAR test can be used to determine if the MCAR assumption is 
met.[34], [35]  However, this test is not appropriate for application to these data.  While the original 
test has been adapted to accommodate arbitrary missingness, the non-binary covariates come from 
binomial distributions, some of which have small probabilities.  This drove the data to depart from 
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univariate normality (at least one covariate had p < 0.05 for the Shaprio-Wilk test at each time-
point) as well as multivariate normality (Doornik-Hansen test values of p < 0.0001 at all time-
points). 
Because no broadly applicable test was available to ascertain if the MCAR assumption was 
violated, indicator variables for missing data were generated to determine if any were statistically 
significant in predicting ACR episodes.  These variables were assigned a value of one if the datum 
was missing and zero if it was observed. 
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4.0  STUDY DESIGN AND IMPLEMENTATION 
4.1 STUDY HYPOTHESES 
The hypotheses examined within this study stemmed from previous a cross-sectional study 
conducted within the University of Pittsburgh,[23] and was supported by observations from other 
findings in the literature.[15], [26], [36], [37]  The aim of the study was to create a predictive statistical 
model that would predict ACR episodes.  Within this study a predictive model is defined as one 
which would indicate changes in the allograft recipients’ immune system during the visit prior to 
the occurrence of ACR (i.e., if a patient experienced ACR at 90 days post-Tx, a predictive model 
should indicate a change based on that patient’s immunological profile at 30 days post-Tx). 
The study was designed to explore whether or not the proportion of TREG relative to the 
rest of the CD4+ T cell population could be used as a predictor of rejection episodes.  TREG have 
been shown to suppress T cell reactivity in a dose-dependent fashion and correlate with ACR 
episodes.[18]  As such, the first hypothesis for the study was whether the proportion of TREG from 
CD4+ T cells could be used to predict patient ACR episodes. 
Decreased prevalence of terminally-differentiated effector memory T cells that were also 
CD45RA+ (CD8 TEMRA), was previously shown to be cross-sectionally correlated with patients 
undergoing ACR.[23]  It was hypothesized that there may be a longitudinal correlation between the 
proportion of CD8 TEMRA versus the remainder of patients’ CD8+ T cell populations.  As a result, 
the second hypothesis tested in this study was that the proportion of CD8 TEMRA relative to all 
CD8+ T cells within patients would predict ACR episodes. 
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The third, and final, hypothesis to be tested in this study resulted from a finding that patients 
characterized as “reactive” (neither tolerant nor experiencing ACR) had elevated levels of CD4+ 
CD45RO+ (CD4 TEM) T cells compared with kidney transplant recipients who appeared 
tolerant.[23]  Resultantly, the third hypothesis to be tested in this study was that the proportion of 
CD4 TEM out of all CD4+ T cells within patients would predict ACR episodes. 
4.2 STUDY IMPLEMENTATION 
The data used for this thesis were obtained from blood samples collected as part of a parent clinical 
study at the University Hospital and Christ Hospital in Cincinnati, Ohio.  The parent study was 
designed as a 12-month, prospective, randomized, dual center, open label pilot study to evaluate 
the safety and efficacy of Myfortic® (mycophenolic acid) loading regimens in combination with 
Simulect® (Basiliximab) induction vs. Thymoglobulin induction alone and with Prograf® 
(tacrolimus) in early corticosteroid withdrawal (hereafter referred to as CWT).  This clinical study 
collected data relevant to standard-of-care treatment for renal transplant recipients; however, only 
demographic data, date of transplant, and rejection episode dates and severity, were made available 
to the University of Pittsburgh’s research group. 
From the 61 patients enrolled in the CWT, this study’s cohort was selected from any patient 
who agreed to volunteer additional blood samples for our subordinate lymphocyte characterization 
and analysis.  All of the CWT’s participants had the option to enroll or refuse enrollment in our 
characterization study while remaining part of the CWT.  Samples for this current study were 
collected from 2011 to 2013.  Forty patients donated blood samples this study.  Of those, five were 
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excluded due to pretreatment with an additional drug, not in the original study design.  Samples 
for this current study were collected from 2011 to 2013 (as discussed in Section 5.1.2.). 
Demographic comparisons of the participants enrolled in the current study were made.  The 
two-tailed Pearson χ2 test was used for testing sex and race.  The two-sided T-test was used for 
patient age at the time of transplant, and a comparison of proportion test was used for number of 
patients.  No test was performed on ethnicity due to complete homogeneity within the study 
population.  Fisher’s exact test was used to assess statistical significance of patients experiencing 
ACR episodes between groups. 
A panel of fluorochrome-conjugated antibodies was developed to characterize the makeup 
of peripheral blood leukocyte.  The panel examined the proportion of three cell types known to be 
correlated in a cross-sectional manner with ACR: TREG, CD4 TEM, and CD8 TEMRA. 
4.3 BLOOD SAMPLE ACQUISITION 
Participants were asked to give up to 75 mL of blood (70 mL in sodium-heparin test tubes and 5 
mL in a serum-separating test tube) at each of the following time-points: before transplantation 
(pre-Tx), 30-; 90-; 180-; 270-; and 360-days after transplantation (post-Tx).  The acceptable 
windows were ±3 days for the 30-day sample, and ±7 days for all other post-Tx samples.  The pre-
Tx samples could be obtained any time prior to the administration of preconditioning or induction 
drugs.  These samples were then shipped overnight to the University of Pittsburgh’s Starzl 
Transplant Institute.  Samples that took greater than 24 hours to arrive were discarded. 
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4.4 PHENOTYPIC ANALYSIS OF LYMPHOCYTES 
Lymphocyte counts were obtained from whole blood samples using the automated cell counter.  
Approximately 1.2 mL of whole blood was retained from the sample for use in staining and flow 
cytometry analysis.  The lymphocytes in the remainder of the samples were then separated via 
Ficoll-Paque suspension and centrifugation at 1,200 rpm in a centrifuge.  The suspended 
lymphocyte layer was combined and washed within 30 minutes of centrifugation using 1640 RPMI 
and bovine serum albumin (BSA) solution under sterile conditions.  The cells from the sample 
were counted visually using a hemocytometer and they were preserved cryogenically in a solution 
of 10% dimethyl sulfoxide (DMSO) in bovine serum albumen (BSA) for follow-on studies. 
4.4.1 Leukocyte Preparation 
The cells intended for analysis via flow cytometry were stained with fluorochrome-conjugated 
monoclonal antibodies for CD3, CD4, CD8, CD45RO, CD45RA, CD62L, CD127, and CD25 
purchased from eBioscience and Beckton Dickinson.  Upon staining, the cells were kept at 4°C in 
the dark for 30 minutes, and then washed and fixed using 1% paraformaldehyde in DPBS.  For the 
analysis of TREG, eBioscience fixation/permeabilization solutions were utilized to allow 
intracellular staining of FoxP3.  Samples were acquired by flow cytometry within 2 hours of 
staining, and the raw data output was analyzed with BD’s FACSDiva software.  All statistical 
analysis of FACSDiva output was conducted using Stata SE 14 software. 
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4.4.2 Data Acquisition 
Proportional data was used throughout this analysis, and shown in percentages.  The number of 
cells from which the percentages are derived are always larger than 100, often greater than 1,000 
or 10,000, so the large number approximation is appropriate for any given observed datum.  The 
system by which the data is obtained is called a gating strategy, because the data are derived by 
drawing a polygon around areas in scatter plots that correspond to cells that correlate to markers 
either being present or absent in the cells.  Figure 4.1 shows the gates for selecting TREG, CD4 
TEMRA, and CD8 TEMRA populations from their parent populations, namely T cells, CD4+ T cells 
and CD8+ T cells, respectively. 
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Figure 4.1: Collection Gates Figure 4.1: Collection Gates 
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5.0  RESULTS 
5.1 DATA DESCRIPTION 
The CWT randomized subjects to two arms.  Those that volunteered for this study were 
similar across both treatment groups, with the exception of sex (Table 5.1).  Although sex is close 
to being statistically significant, none of the demographic differences reach statistical significance 
at the p = 0.05 level.  There was no statistical difference between the number of patients that 
experienced at least one ACR episode. 
Table 5.1: Study Participant Demographics 
5.2 MISSING DATA 
Eleven of 35 patients had data collected for every planned collection time-point.  Nine patients’ 
data were left-truncated, seven patients’ data were right-truncated, and an additional eight patients 
had one or more time-point of missed data collection.  In total, approximately 26.7% of the data 
was missing from the 35 patients.  Further examination of the MCAR assumption was required 
before application of GEE.  A depiction of the data collected can be seen in Figure 5.1 in which 
 Thymoglobulin Basiliximab P-value 
Number of Patients 20 15 0.552 
Age at Tx (years) 51.1 ± 14.4 
(Range 28 to 71) 
56.7 ± 12.2 
(Range 37 to 79) 
0.231 
Sex 10 male, 10 female 12 male, 3 female 0.069 
Race 16 Caucasian, 4 Black 12 Caucasian, 3 Black 1.000 
Ethnicity 20 Non-Hispanic/Latino 15 Non-Hispanic/Latino N/A 
ACR 7 2 0.244 
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collected data for a patient a given time-point is shown in green (if there was no ACR) or red (if 
there was a biopsy-proven ACR episode after the sample collection but before the next sample 
collection).  Missing data are shown by a blank cell. 
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Patient Pre-Tx 30 Days 90 Days 180 Days 270 Days 360 Days 
01           65.8 
03           35.8 
06         83.7 90.4 
12         68.4 70.8 
17     62.2   40.6 62.9 
19       79.6 82.2 79 
23     73.2 70.8   68.6 
26   1.61 41.1 33.6 61.4 60.9 
28       85.2 76.9 74.1 
30 68.1 66.6 70.1 69.3 73.6 70.7 
31 81.8 77.5 62.7 74.2   71.2 
32 62.9 16.1 32.4 32.8 52.2 100 
35 60.3 5.03 7.25 21.5 18.5 19 
36 68.4 34   37.5 46.1 47.3 
37 92.3 78 74.7 76.4 79.4 78.3 
47 27.9 75.4 81.8 83.3 74.6 84.5 
49 32.5 0.898 15.1 28.6 44.7 47.8 
54 84.4 85.8 83.6 81.3 84.6 77.2 
56 51.8 8.15 21.7 21.8 18.5 16.2 
57 74.8 60.6 66.4     53.6 
59 81.3 50.2 66.6   64.9 66.8 
61 60.9 70 76.1 40.8 12.8 23.2 
76 79.5 47.1 49.9 52.1 38.3   
78 82.3 49.1 63.4   60.6 57.1 
79 72.1 4.81 14.1 21.4     
82 70.6 3.99 8.72 41.6 100   
83 74.2 55.6 57.7   55.2 55.8 
84 82.4 36.8 36.6 50.9 70.5 72.3 
85 77.8 32.4   39.5   30.7 
89 45.8 22.4 34.3       
90 75.8 53.9 63.4 59.2     
92 68.1 16.7 54.6 64.9 59.5 66 
93 75.1 27.7 29.7 47.1   40.6 
96 73   38.3 42.5 36.2   
97 82.7 15.9 24.3 45     
 
Figure 5.1: Collected Data 
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Although the level of data missed from collection is high the number of samples received 
for each time-point is consistent: for each of the six time-points from pre-Tx to 360 days post-Tx, 
the number of collected data points was 26, 26, 27, 25, 24, and 28, respectively.  On average 4.6 
samples were collect for each subject in the study.  Thirteen patients had missing data only as the 
result of truncation due to late entry into the study or premature termination of the study 
(accounting for 76% of the missing data).  Eleven of the 35 patients had missing data not accounted 
for by study implementation, which equates to 10.8% of the total time-points which may have been 
collected from the 35 enrollees. 
None of these indicator variables was found to be statistically significant in GEE analysis 
where ACR episodes were held as the independent variable and each missing indicator was tested 
as a dependent variable, in turn.  Because that missing data due to study design or implementation 
does not necessarily violate the MCAR assumption and no missing data were statistically 
significant in predicting the outcome of interest, the MCAR assumption for these data was deemed 
appropriate.[38] 
5.3 PARAMETER SELECTION 
Parameters, and their corresponding coefficients’ p-values, may be seen in Table 5.2 (p < 0.15 are 
italicized).  Parameters other than TREG, CD4 TEMRA, and CD8 TEMRA were included due to their 
biological relevance in T cell immunity with the possibility that they may help to refine any 
predictive relationships that might exist between the two variables of interest and ACR events. 
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Table 5.2: GEE Single-Parameter Model Values 
Parameter Coefficient p-value  Parameter Coefficient p-value 
Age, centered -.04536 0.109  CD25hi .0480918 0.416 
Days post-Tx -.0039507 0.117  TREG -.0007007 0.469 
Treatment 1.141206 0.149  CD4 TEM -.0048596 0.760 
CD4 .0113613 0.241  CD4 TEMRA .0717864 0.051 
CD8 -.0164905 0.118  CD8 TEM .0011368 0.953 
CD4/CD8 .0630022 0.671  CD8 TEMRA .014741 0.435 
5.4 MODEL CONSTRUCTION 
For the purpose of preliminary GEE model construction an AR1 correlation structure was 
assumed.  In addition to the five parameters that met the inclusion criterion, the variables TREG, 
CD4 TEM, and CD8 TEMRA were added to Models A, C, and E, respectively. 
Model A was built using the parameters Age (centered), Days post-Tx, Treatment, CD8, 
CD4 TEMRA, and TREG.  GEE analysis of the model showed that it was significant (Wald χ2 p = 
0.0095) but it contained on covariate that was not statistically significant, Days post-Tx.  The 
details for Model A can be seen in Table 5.3. 
Table 5.3: Model A Values 
Parameter Coefficient p-value  Parameter Coefficient p-value 
Age, centered 0.035529 0.012  CD8 0.0216521 0.002 
Thymoglobulin 1.239464 0.026  CD4 TEMRA 0.0738930 0.062 
Days post-Tx 0.0029239 0.900  TREG 0.0145422 0.267 
 
Days post-Tx was removed from the covariates in Model A because it had the highest p-
value, and Model B was built from the five remaining covariates.  Model B was statistically 
significant (Wald χ2 p = 0.0059), but TREG was not a statistically significant covariate (p = 0.245).  
Details for Model B can be found in Table 5.4. 
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Table 5.4: Model B Values 
Parameter Coefficient p-value  Parameter Coefficient p-value 
Age, centered 0.0350208 0.010  CD8 0.0211845 0.001 
Thymoglobulin 1.120552 0.012  CD4 TEMRA 0.0736068 0.061 
    TREG 0.0140173 0.245 
 
Model C contained the five covariates found to be statistically significant in univariate 
analysis as well as CD4 TEM.  Model C achieved statistical significance (Wald χ2 p = 0.0061), but 
it contained covariates that failed to reach statistical significance.  Details for Model C can be seen 
in Table 5.5. 
Table 5.5: Model C Values 
Parameter Coefficient p-value  Parameter Coefficient p-value 
Age, centered -0.098 0.007  CD8 -0.077 0.013 
Thymoglobulin 2.419 0.026  CD4 TEMRA 0.152 0.058 
Days post-Tx -0.0006 0.834  CD4 TEM 0.028 0.405 
 
Days post-Tx was removed from the pool of covariates in Model C to produce Model D’s 
covariate pool because it had the highest p-value.  Model D was statistically significant (Wald χ2 
p = 0.0121), but it contained one covariate that was not, CD4 TEM.  Values for Model D can be 
seen in Table 5.6. 
Table 5.6: Model D Values 
Parameter Coefficient p-value  Parameter Coefficient p-value 
Age, centered -0.099 0.006  CD8 -0.079 0.015 
Thymoglobulin 2.503 0.010  CD4 TEMRA 0.152 0.057 
    CD4 TEM 0.027 0.407 
 
Model E was constructed using the third covariate of interest, CD8 TEMRA, in addition to 
the five covariates found to be statistically significant in univariate analysis.  Model E was 
statistically significant (Wald χ2 p = 0.0198), but it contained three covariates that were not 
statistically significant at the p < 0.05 threshold.  See Table 5.7 for Model E details. 
 31 
Table 5.7: Model E Values 
Parameter Coefficient p-value  Parameter Coefficient p-value 
Age, centered 0.0335643 0.006  CD8 0.0247909 0.005 
Thymoglobulin 1.123874 0.020  CD4 TEMRA 0.0777823 0.142 
Days post-Tx 0.0029216 0.858  CD8 TEMRA 0.0329762 0.249 
 
The covariate with the highest p-value was removed from the covariates in Model E to 
produce Model F.  Model F was statistically significant (Wald χ2 p = 0.0032), but it contained two 
covariates that failed to reach statistical significance, CD4 TEMRA and CD8 TEMRA. 
Table 5.8: Model F Values 
Parameter Coefficient p-value  Parameter Coefficient p-value 
Age, centered 0.032653 0.005  CD8 0.0252462 0.004 
Thymoglobulin 1.033318 0.010  CD4 TEMRA 0.0789165 0.149 
    CD8 TEMRA 0.0334378 0.253 
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6.0  DISCUSSION 
The analysis of the data showed that neither of TREG, CD4 TEM, nor CD8 TEMRA proportions in 
peripheral blood were associated with ACR events.  None of the variables of interest was 
independently statistically significant in this regard nor were they statistically significant when 
forced into models containing other statistically significant covariates. 
Five covariates were identified that were potentially predictive of ACR episodes: Age 
(centered), Days post-Tx, Treatment, CD4 TEMRA, and CD8.  These five predictors have been 
previously described in the literature as being correlated with ACR episodes.  The positive or 
negative influence of the coefficients for Days post-Tx, Treatment, CD4 TEMRA, and CD8 are in 
line with previous findings.[1], [16], [37]  Of note, the literature is mixed in regard to whether 
Thymoglobulin or Basiliximab therapies are more likely to lead to ACR episodes, with some 
studies concluding that one treatment is more beneficial while others conclude the opposite.[16]  
Also in line with previous studied, patients in this study experienced a preponderance of ACR 
episodes between transplant and 90 days post-Tx; a common problem for kidney tolerance in the 
clinic.[19] 
Recipient age is known to be a predictor of renal transplant rejection episodes, however 
increasing age has been shown to be associated with increased risk for ACR,[39] while in this study 
the opposite was observed.  It has also been noted that increased deceased donor age increases the 
risk of ACR episodes.[39]  Due to this study not being provided with donor organ age data, the 
correlation between Days post-Tx and ACR episodes may be the product of a confounding 
variable. 
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There are two very important caveats to the lack of statistical significance found in our 
subsets of interest as compared with previous literature: first, two of the markers were chosen 
based upon a study using a different induction agent;[23] and second due to the small number of 
patients enrolled in the study, the analysis may have not had enough power to detect a true predictor 
of ACR. 
 Different induction modalities have varying means of action, and effects, upon recipients’ 
immune system.  The differences noted in populations of TREG, CD4 TEM, and CD8 TEMRA came 
from studying patients that had undergone induction therapy using Alemtuzumab.  Thymoglobulin 
is a T cell depleting agent, whereas Alemtuzumab depletes not only lymphocytes, but also B cells.  
The presence or absence of these cells has been shown to effect graft tolerance.[7]   
6.1 ANALYSIS LIMITATIONS 
These data did not appear to violate the MCAR assumption.  However, due to the high amount of 
missing data and no established test for the assumption, discussion of addressing the missing data 
is warranted.  Should the collected data not reflect the population-at-large, the results of the 
analysis could contain bias of the estimators or their statistical significance. 
Two common methods for dealing with missing data, line (subject) deletion and multiple 
imputation (MI), were both inappropriate for application here.  If line deletion were used, 
approximately 69% of the subjects from the study would be eliminated from analysis, leaving a 
sample too small for any meaningful discussion.  MI methodology would not aid analysis because 
MI addresses missing values for a given time-point based upon other variable values for that same 
time-point.  Given that all lymphocyte population data is derived from the presence or absence of 
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a blood sample, there is almost no missing data for any given patient-time-point unless all of the 
data for that time-point is missing. 
 Beyond the common methods mentioned above, there exist additional methodology for 
analyzing missing data, but these methods are computationally intensive, lack explicit algorithms 
for general use, and/or rely upon untestable hypotheses whose violation results in highly biased 
outcomes given non-normal distributions.[40], [41]  Three of these methods are the selection model, 
pattern mixture model, and shared parameter model.  The selection model is inappropriate as it 
relies on the assumption that data measures can predict missingness, and the left- and right-
truncation subjects are known to have missingness not related to their observed values.  The pattern 
mixture model was not used because it relies upon there being relatively few patterns of 
missingness within the data relative to its clusters, and this assumption was violated by there being 
16 patterns of missingness, eight of which were unique, among the 35 subjects.  The shared 
parameter model could not be used on this data because it relies on the assumption that within a 
given subject the chance of a binary outcome increases or decreases in a linear fashion over time, 
which is known to be false in the observed population for the parameters of interest.  Lastly, these 
three models are well-suited for dropout (right truncation) of data in which data for a given subject 
exists until the point that the data is censored.  Right truncation was only observed in seven of 35 
patients, lending further merit to these models not being applied to these data.  It has been shown 
that mixed-effect models can be tailored to produce more efficient estimators than GEE 
methodology in some cases when truncation and random missing data are present, however since 
the assumptions of GEE were met, no mixed-effect models were fit to these data. 
Exploration of the data’s missingness showed that the amount of data missing or present 
relative to the other time-points was similar across all time-points.  There were no outliers in this 
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regard.  Given that all available methods of analysis would have a violated assumption if applied 
to these data, it was determined that GEE methodology was best suited to analysis in this study. 
Although GEE analysis was deemed an appropriate method for use with these data, one of 
the assumptions, namely MCAR, might be called into question since Little’s MCAR test was not 
applicable here.  Although much of the data was missing, its missingness did not depend upon the 
outcome of interest, as assessed by the missing data’s lack of correlation to ACR episodes.  Also 
of note is that 76% of the missing data was due to a cause independent of ACR episodes, due to 
left- and right-truncation late implementation of this study and termination of the parent study, 
rather than lack of patient follow-up (which might be negatively correlated with patient self-care 
and thus with ACR episodes). 
While no power calculations were performed for this study’s analysis, other work suggests 
that the sample size achieved in this study may have been too small to detect statistically significant 
predictors of ACR episodes.  Even with a low level of intra-cluster correlation and a relative risk 
greater than three, single binary exposure/outcome correlations require more than 70 clusters to 
achieve 90% power at the desire significance level of 0.05.[35]  Although most of the covariates in 
this study were not binary, the power simulations serve as an example that many more participants 
may be necessary in a study of this type in order to detect statistically significant covariates, 
especially those that have been shown to be linked in cross-sectional studies by many previous 
investigators.[6], [15], [17], [18], [22], [24], [26], [36], [37] 
The coefficients for the parameters of interest mirrored the positive or negative effects 
expected of TREG, CD4 TEM, nor CD8 TEMRA on future ACR episodes.  As such, their failure to 
reach statistical significance of p < 0.05 does not refute previous findings, but rather highlights the 
need for more information to be gathered in similar cohorts to elucidate the predictive strength of 
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these markers.  Such further studies should also explore the ratio of TREG to the two memory 
subsets of interest, since they were shown to be correlated with patients undergoing ACR as 
compared with quiescent kidney allograft recipients.[23]  Unfortunately, due to sparse data in this 
study, modeling of these ratios was too noisy for meaningful analysis. 
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7.0  CONCLUSION 
The analysis of these data showed that TREG, CD4 TEM, and CD8 TEMRA cell populations did not 
statistically significantly predict ACR episodes, possibly due to lack of analytic power stemming 
from missing data and small sample size.   
While none of the hypotheses were confirmed, if the results of the single-variable models 
are reflective of the kidney transplant population, clinically useful inference can be made.  Of 
interest, CD4 TEMRA has been shown to be predictively associated with liver transplant ACR, [37] 
and CD8 proportions have also shown association with kidney ACR episodes.[26]  With this in 
mind, further exploration of these data and studies with more robust data collection, could reveal 
that either/both CD4 TEMRA and CD8 are predictive of ACR. 
From a public health perspective, the ongoing challenge of discovering a minimally-
invasive technique for predicting ACR remains.  This analysis has shown that although the 
hypothesized parameters did not predict rejection, other markers may be able to do so.  
Development of such a technique is of paramount importance as it greatly benefits transplant 
recipients, reduces the burden of health care provision, and will help to alleviate the persistent 
problem of lower than necessary donor organ supply. 
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